HALBERD CORP - HALB STOCK NEWS

Halberd (OTC PINK: HALB) has released the results of its WatchDawg® Pilot Study for PTSD treatment. The study involved 10 military veterans who received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies. Participants wore wrist monitors and used mobile phones to upload vital sign data to Athena GTX's FDA-cleared Device Management Suite.

The study revealed consistent positive impact of the treatment, with data indicating improved overall health. Monitored indicators included heart rate, blood oxygen level, respiration rate, and skin temperature. Dr. Mark Darrah, CEO of Athena GTX, stated that the results were very encouraging and met all objectives. The company plans to proceed to a 100-patient Phase 1 clinical trial, incorporating feedback to improve the treatment protocol.

Halberd (OTC PINK: HALB) has secured a significant contract with Defense Atomics to advance research on PTSD and TBI treatment. The partnership involves:

1. Funding for FDA IND study using Halberd's LDX technology and Athena's WatchDawg™ monitoring.

2. A pilot study combining Defense Atomics' CRISPR/Nanotechnology Stem Cell treatment with Halberd/Athena's protocols.

3. Commercial packaging of LDX for marketing to physician groups under compounding laws.

4. Integration of WatchDawg technology for real-time monitoring of treatment efficacy.

The global PTSD treatment market is projected to reach $1.04 billion by 2030, while the TBI treatment market could grow to $5.53 billion by 2030, highlighting significant growth opportunities for this partnership.

Halberd (OTC: HALB) has issued a letter to shareholders announcing the evolution of its patented LDN+ into WatchDawg™, a solution aimed at reducing veteran suicides. Utilizing a combination of Low Dose Naltrexone and a muscle relaxer MethoCarbamol, WatchDawg is designed to offer relief for various conditions including PTSD, addiction, and depression.

The pilot study data is promising, showing significant improvements in patients and reducing reliance on opioids. The product incorporates advanced wearable technology for real-time health monitoring, providing insights into patient health trends and enabling better management of PTSD and related conditions. The company plans to commercialize WatchDawg without requiring FDA clearance initially, using compounding pharmacy rules, and will seek FDA Fast Track designation based on pilot study outcomes.

Halberd is also exploring the potential to franchise the WatchDawg business model to expand its reach and help more veterans and individuals dealing with mental health issues.

Halberd (OTC: HALB) has issued a shareholder letter focusing on their evolving PTSD treatment, WatchDawg™. Key points include:

1. LDN+ has evolved into LDX, combining drug therapy with adjunct treatments and 24/7 monitoring.

2. Early pilot study data from veteran volunteers shows promising results, including lower heart rates, reduced stress levels, and improved vital sign stability.

3. The company is pursuing a faster, lower-cost alternative to FDA clearance through compounded pharmacy solutions.

4. WatchDawg™ includes pharmaceuticals, therapeutic services, digital health solutions, and support programs.

5. Halberd is transitioning to Phase 1 and plans a comprehensive 150-participant safety and efficacy study.

Halberd (OTC PINK: HALB) issued a shareholder letter highlighting recent developments. The company's Tri-aX™ TBI nasal spray has shown promising results in preclinical studies at Mississippi State University for treating traumatic brain injury (TBI). The Department of Defense (DoD) selected Halberd's pre-proposal and invited a full application for funding up to $700,000 under the Emerging Topics Research Award.

The research will focus on establishing patterns of change in blood and brain biomarkers of injury at different TBI levels. Halberd emphasizes the need for secrecy regarding their proprietary formulation due to competitive concerns. The company plans to submit a detailed proposal by October 3rd and expects a decision within months.

Halberd (OTC: HALB) has announced promising initial results from Phase II testing of its Tri-Ax™ nasal spray for mitigating traumatic brain injury (TBI) effects. The tests, conducted at Mississippi State University, show that higher impact forces lead to step-wise changes in motor activity levels. Importantly, TBI-induced motor activity changes were significantly improved when Tri-Ax™ was administered one hour post-impact at one of the higher impact forces.

The company sees potential applications in military and civilian contact sports, law enforcement, hospitals, and emergency response units. Halberd is also developing an auto-nasal injector with partner Athena GTX for point-of-injury care. The market potential is considered substantial if ongoing tests continue to support initial optimism.

Halberd (HALB), in collaboration with Athena GTX, is progressing toward innovative treatments for depression, anxiety, substance use disorders, and PTSD, conditions prevalent in both the general population and military. With statistics showing 93,000 suicides yearly in the Americas, the urgency for effective solutions is clear. Halberd’s work includes the patented LDN+ (Low Dose Naltrexone and Cyclobenzaprine), which has shown promise in enhancing opioid receptor function and reducing inflammation. Their Watchdawg™ program integrates pharmacological interventions with psychological support and therapies like yoga. Additionally, their nasal spray for PTSD and TBI has demonstrated potential in reducing neuro-degenerative markers by over 50% in animal studies. This collaboration aims to address significant gaps in current treatment methods and offers hope for improved mental health solutions globally.

Halberd 's two active programs for traumatic brain injury treatment align with the new U.S. House bill aiming to reduce veteran suicide. The company's patented drug LDN+ and nasal spray show promise in treating PTSD, suicide ideation, and addiction. The bill, named after two Marines lost to suicide, aims to provide mental health support for transitioning veterans.

Halberd has initiated pre-pilot trials with military veterans for its patented LDN+ drug, designed to combat PTSD and suicidal ideation. The drug aims to address PTSD and suicidal thoughts by acting as an antagonist against chemical and alcohol use disorders, while also relieving pain and anxiety. The trials involve initial participants, with plans for wider pilot and safety studies in the near future. Halberd will provide updates as the clinical trial progresses.